AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8087786 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiation treatment
Number of subjects: 0
Study 2514676 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine 100 mg/day
Number of subjects: 88
Study 2514676 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine 150 mg/day
Number of subjects: 88
Study 2514676 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine 200 mg/day
Number of subjects: 88
Study 7193520 — intervention group
Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum on Day 1
Number of subjects: 40
Study 7193520 — intervention group
Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum on Day 14
Number of subjects: 40
Study 7193520 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin and cisplatin (no specific day mentioned)
Number of subjects: 40
Study 31060757 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon pulmonary angioplasty (BPA)
Number of subjects: 15
Study 29339901 — intervention group
Group type: EXPERIMENTAL
Intervention: IRGO (Isocentric Reciprocating Gait Orthosis)
Number of subjects: 9
Study 29339901 — intervention group
Group type: COMPARATOR
Intervention: IRGO without reciprocating link
Number of subjects: 9
Study 26510526 — intervention group
Group type: EXPERIMENTAL
Intervention: Astym therapy
Number of subjects: 45
Study 26510526 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (sham Astym treatment)
Number of subjects: 45
Study 26510526 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 45
Study 23665753 — intervention group
Group type: EXPERIMENTAL
Intervention: Active movements
Number of subjects: 0
Study 23665753 — intervention group
Group type: COMPARATOR
Intervention: Passive movements
Number of subjects: 0
Study 23665753 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants' own movements as temporally delayed distractors
Number of subjects: 0
Study 22341059 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 100
Study 22341059 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:80,000 epinephrine
Number of subjects: 100
Study 20452716 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia (TIVA)
Number of subjects: 53
Study 20452716 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 53
Study 17565634 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 36
Study 17565634 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole 10 mg
Number of subjects: 36
Study 15810472 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton swab
Number of subjects: 318
Study 15810472 — intervention group
Group type: COMPARATOR
Intervention: Dacron swab
Number of subjects: 318
Study 15810472 — intervention group
Group type: COMPARATOR
Intervention: Cytologic brush
Number of subjects: 318
Study 12150616 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 332
Study 10102601 — intervention group
Group type: COMPARATOR
Intervention: 5% lidocaine ointment
Number of subjects: 10
Study 10102601 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 10
Study 7788259 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical methylene blue staining (1% solution)
Number of subjects: 39
Study 7788259 — intervention group
Group type: COMPARATOR
Intervention: Random biopsy
Number of subjects: 39
Study 2360738 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial artery pressure monitoring
Number of subjects: 170
Study 2360738 — intervention group
Group type: COMPARATOR
Intervention: Radial artery pressure monitoring
Number of subjects: 170
Study 7198462 — intervention group
Group type: EXPERIMENTAL
Intervention: Plafibride at 800 mg/d
Number of subjects: 0
Study 7198462 — intervention group
Group type: EXPERIMENTAL
Intervention: Plafibride at 1600 mg/d
Number of subjects: 0
Study 7198462 — intervention group
Group type: COMPARATOR
Intervention: Alufibrate (control)
Number of subjects: 0
Study 7198462 — intervention group
Group type: EXPERIMENTAL
Intervention: Plafibride and Alufibrate
Number of subjects: 0
Study 31792007 — intervention group
Group type: EXPERIMENTAL
Intervention: Differentially expressed genes (DEGs) identified at E14, E18, E28 stages
Number of subjects: 9
Study 31792007 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional classification of DEGs
Number of subjects: 9
Study 31792007 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific GO terms identified
Number of subjects: 9
Study 31792007 — intervention group
Group type: EXPERIMENTAL
Intervention: Clustering of DEGs
Number of subjects: 9
Study 31792007 — intervention group
Group type: EXPERIMENTAL
Intervention: KEGG pathways identified
Number of subjects: 9
Study 31792007 — intervention group
Group type: EXPERIMENTAL
Intervention: Selected DEGs for verification
Number of subjects: 9
Study 30822124 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic augmented ACL suture repair
Number of subjects: 48
Study 30822124 — intervention group
Group type: COMPARATOR
Intervention: ACL reconstruction (single-bundle, all-inside, semitendinosus technique)
Number of subjects: 48
Study 28792112 — intervention group
Group type: EXPERIMENTAL
Intervention: VSP Er:YAG laser resurfacing (400 mJ in short pulse mode with 50% overlapping and 2.2 J/cm2 in smooth mode)
Number of subjects: 21
Study 28792112 — intervention group
Group type: EXPERIMENTAL
Intervention: VSP Er:YAG laser resurfacing (two passes of 400 mJ in short pulse mode with 50% overlapping)
Number of subjects: 21
Study 28792112 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 21
Study 25867447 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (nicotine patch, nicotine lozenge, bupropion SR, patch and lozenge, or bupropion SR and lozenge)
Number of subjects: 1433
Study 25867447 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch and lozenge combination
Number of subjects: 1433
Study 25867447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1433
Study 24028629 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii supplementation (250 mg/day)
Number of subjects: 271
Study 24028629 — intervention group
Group type: COMPARATOR
Intervention: Control group (no S. boulardii supplementation)
Number of subjects: 271
Study 21301952 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol for an Office‐based Nurse‐administered Intervention (PONI) administered on-site by trained nurses over the course of 3-6 months.
Number of subjects: 80
Study 21301952 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial symptom severity
Number of subjects: 80
Study 19237249 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid therapy (group 3)
Number of subjects: 58
Study 19237249 — intervention group
Group type: COMPARATOR
Intervention: No opioid therapy (group 2)
Number of subjects: 58
Study 19237249 — intervention group
Group type: COMPARATOR
Intervention: No pain or opioid therapy (group 1)
Number of subjects: 58
Study 17249848 — intervention group
Group type: EXPERIMENTAL
Intervention: Garenoxacin 600 mg as intact tablets
Number of subjects: 18
Study 17249848 — intervention group
Group type: EXPERIMENTAL
Intervention: Garenoxacin 600 mg as crushed tablets via NG tube
Number of subjects: 18
Study 17249848 — intervention group
Group type: EXPERIMENTAL
Intervention: Garenoxacin 600 mg as crushed tablets via NG tube with concomitant enteral feeding (Osmolite; 600 mL at 100 mL/h)
Number of subjects: 18
Study 15236891 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 h intravenous hydration
Number of subjects: 0
Study 15236891 — intervention group
Group type: COMPARATOR
Intervention: No intravenous hydration (Control)
Number of subjects: 0
Study 11597795 — intervention group
Group type: EXPERIMENTAL
Intervention: No PORT for low-risk group (n = 31)
Number of subjects: 213
Study 11597795 — intervention group
Group type: EXPERIMENTAL
Intervention: 57.6 Gy during 6.5 weeks for intermediate-risk group (n = 31)
Number of subjects: 213
Study 11597795 — intervention group
Group type: EXPERIMENTAL
Intervention: 63 Gy during 5 weeks for high-risk group (n = 76)
Number of subjects: 213
Study 11597795 — intervention group
Group type: EXPERIMENTAL
Intervention: 63 Gy during 7 weeks for high-risk group (n = 75)
Number of subjects: 213
Study 11597795 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant boost technique (2-week reduction in PORT duration)
Number of subjects: 213
Study 11597795 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative duration of combined therapy
Number of subjects: 213
Study 9145729 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate (875/125 mg) every 12 hours
Number of subjects: 557
Study 9145729 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (500/125 mg) every 8 hours
Number of subjects: 557
Study 7703511 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg sublingually
Number of subjects: 16
Study 7703511 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 5 mg
Number of subjects: 16
Study 3034316 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril maleate 10 mg orally
Number of subjects: 12
Study 3034316 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril maleate 5 mg intravenously
Number of subjects: 12
Study 3034316 — intervention group
Group type: EXPERIMENTAL
Intervention: enalaprilat 5 mg intravenously
Number of subjects: 12
Study 3034316 — intervention group
Group type: EXPERIMENTAL
Intervention: oral administration of 10 mg enalapril maleate
Number of subjects: 12
Study 29423981 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice nurse led health checks
Number of subjects: 11
Study 26486702 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal (ID) influenza vaccine (15 µg)
Number of subjects: 400
Study 26486702 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (IM) influenza vaccine (15 µg)
Number of subjects: 400
Study 25418440 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed primary excision (DPE) with adjusted radiation therapy (RT) dose
Number of subjects: 161
Study 25418440 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) dose of 36 Gy, 41.4 Gy, or 50.4 Gy based on DPE results
Number of subjects: 161
Study 25418440 — intervention group
Group type: COMPARATOR
Intervention: IRS-IV standard treatment without DPE
Number of subjects: 161
Study 24199974 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (TCC) exercise for 3 months, 40 min per session, 7 times per week
Number of subjects: 42
Study 24199974 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 42
Study 20007415 — intervention group
Group type: EXPERIMENTAL
Intervention: Room temperature local anaesthetic
Number of subjects: 50
Study 20007415 — intervention group
Group type: COMPARATOR
Intervention: Refrigerated local anaesthetic
Number of subjects: 50
Study 18806105 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron + Folic Acid + Retinol + Riboflavin (IFAB)
Number of subjects: 366
Study 18806105 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron + Folic Acid + Retinol (IFA)
Number of subjects: 366
Study 18806105 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron + Folic Acid + Riboflavin (IFB)
Number of subjects: 366
Study 18806105 — intervention group
Group type: COMPARATOR
Intervention: Iron + Folic Acid (IF)
Number of subjects: 366
Study 15684258 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 0.5 mg.kg(‐1)
Number of subjects: 320
Study 15684258 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1.0 mg.kg(‐1)
Number of subjects: 320
Study 15684258 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5 mg.kg(‐1)
Number of subjects: 320
Study 15684258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study 11850268 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome) - 2 mg/kg body weight
Number of subjects: 0
Study 11850268 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B deoxycholate (AMB-DOC) - 0.6 mg/kg body weight
Number of subjects: 0
Study 10477253 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (counseling to reduce child's intake of saturated fat and cholesterol)
Number of subjects: 1062
Study 10477253 — intervention group
Group type: COMPARATOR
Intervention: Control (brief dietary discussion)
Number of subjects: 1062
Study 8557971 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20-40 mg/day)
Number of subjects: 18
Study 8557971 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine-GITS (30-60 mg/day)
Number of subjects: 18
Study 8557971 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (100 mg/day for 2 weeks)
Number of subjects: 18
Study 8557971 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (75 mg/day for 1 week)
Number of subjects: 18
Study 1956698 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid synthetic polypeptide vaccine containing epitopes from four proteins of Plasmodium falciparum
Number of subjects: 185
Study 1956698 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA phenotyping of low responders
Number of subjects: 185
Study 6215831 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine 75 mg b.i.d.
Number of subjects: 16
Study 6215831 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine 100 mg b.i.d.
Number of subjects: 16
Study 6215831 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Zimelidine and Desipramine)
Number of subjects: 16
Study 31818340 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical care for symptomatic RTIs
Number of subjects: 60678
Study 31818340 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare utilization for common cold, influenza, and acute upper RTIs
Number of subjects: 60678
Study 31818340 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare utilization rates
Number of subjects: 60678
Study 31818340 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical interventions for RTIs
Number of subjects: 60678
Study 28509614 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up calls (TFU) within 72 hours after discharge
Number of subjects: 0
Study 28509614 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study 28509614 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up calls (TFU)
Number of subjects: 0
Study 26938214 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral flucloxacillin
Number of subjects: 113
Study 26938214 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fusidic acid
Number of subjects: 113
Study 26938214 — intervention group
Group type: COMPARATOR
Intervention: Oral and topical placebos
Number of subjects: 113
Study 24746844 — intervention group
Group type: EXPERIMENTAL
Intervention: Paramedics' experiences and challenges in conducting out-of-hospital stroke trials
Number of subjects: 14
Study 24746844 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitators identified
Number of subjects: 14
Study 24746844 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers identified
Number of subjects: 14
Study 24746844 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation of paramedics
Number of subjects: 14
Study 24746844 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall feasibility of ultra-acute stroke research
Number of subjects: 14
Study 22549668 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompression splints
Number of subjects: 20
Study 22549668 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 20
Study 19417580 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz plus two NRTIs
Number of subjects: 753
Study 19417580 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/r plus two NRTIs
Number of subjects: 753
Study 19417580 — intervention group
Group type: COMPARATOR
Intervention: lopinavir/r plus efavirenz (NRTI-sparing)
Number of subjects: 753
Study 19417580 — intervention group
Group type: COMPARATOR
Intervention: NRTI-sparing regimen
Number of subjects: 753
Study 16575724 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg/day) for 3 weeks
Number of subjects: 44
Study 16575724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 16575724 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 44
Study 16575724 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline and Placebo
Number of subjects: 44
Study 14644780 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-axis (SA) approach
Number of subjects: 17
Study 14644780 — intervention group
Group type: COMPARATOR
Intervention: Long-axis (LA) approach
Number of subjects: 17
Study 11013866 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese boys
Number of subjects: 35
Study 11013866 — intervention group
Group type: COMPARATOR
Intervention: Control group boys
Number of subjects: 35
Study 8657524 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast with 25% of daily phenylalanine allowance and lunch with 30%
Number of subjects: 7
Study 8657524 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast with 50% of daily phenylalanine allowance and lunch with 10%
Number of subjects: 7
Study 8657524 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast with 75% of daily phenylalanine allowance and lunch with 10%
Number of subjects: 7
Study 8657524 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast with unequal distribution of phenylalanine allowance
Number of subjects: 7
Study 1632391 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin, 40 mg twice daily for 7 to 10 days before PTCA and continued for 6 months.
Number of subjects: 360
Study 1632391 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 to 10 days before PTCA and continued for 6 months.
Number of subjects: 360
Study 6475822 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg zinc added to vitamin and mineral supplements)
Number of subjects: 213
Study 6475822 — intervention group
Group type: COMPARATOR
Intervention: Control group (no zinc supplementation)
Number of subjects: 213
Study 31375452 — intervention group
Group type: EXPERIMENTAL
Intervention: General radiomic signature
Number of subjects: 54
Study 31375452 — intervention group
Group type: COMPARATOR
Intervention: Targeted therapy
Number of subjects: 54
Study 31375452 — intervention group
Group type: COMPARATOR
Intervention: Nontargeted therapy
Number of subjects: 54
Study 30518050 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut consumption (15% of energy) for 2 years
Number of subjects: 149
Study 30518050 — intervention group
Group type: COMPARATOR
Intervention: Control group (habitual diet, abstaining from walnuts)
Number of subjects: 149
Study 27236883 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine combined with electrical stimulation at Baihui (DU20), Yintang (EX-HN3), and Neiguan (PC6) before dexmedetomidine anesthesia.
Number of subjects: 122
Study 27236883 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine anesthesia (control group).
Number of subjects: 122
Study 23417236 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 × 4 mL hylastan
Number of subjects: 391
Study 23417236 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 × 4 mL hylastan
Number of subjects: 391
Study 23417236 — intervention group
Group type: COMPARATOR
Intervention: Steroid (IA methylprednisolone acetate 40 mg)
Number of subjects: 391
Study 23417236 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (2 × 4 mL hylastan, 1 × 4 mL hylastan, steroid)
Number of subjects: 391
Study 22331761 — intervention group
Group type: EXPERIMENTAL
Intervention: Test: 0.2 mg misoprostol tablet
Number of subjects: 20
Study 22331761 — intervention group
Group type: COMPARATOR
Intervention: Reference: branded misoprostol tablet
Number of subjects: 20
Study 20655543 — intervention group
Group type: EXPERIMENTAL
Intervention: High-DHA algal oil (∼200 mg/d of DHA)
Number of subjects: 0
Study 20655543 — intervention group
Group type: COMPARATOR
Intervention: Vegetable oil (placebo, containing no DHA)
Number of subjects: 0
Study 17666627 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior colporrhaphy with tailored low-weight polypropylene mesh
Number of subjects: 202
Study 17666627 — intervention group
Group type: COMPARATOR
Intervention: Anterior colporrhaphy without mesh
Number of subjects: 202
Study 15861352 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 64
Study 15861352 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 64
Study 15861352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 12393771 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal tube
Number of subjects: 22
Study 12393771 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask
Number of subjects: 22
Study 10196731 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-measured blood pressure readings (2 readings, one at work and one at home, over 3 consecutive days)
Number of subjects: 43
Study 10196731 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-measured blood pressure readings (2 readings, one at work and one at home, over 8 or more consecutive days)
Number of subjects: 43
Study 7777878 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil and placebo (n = 13)
Number of subjects: 35
Study 7777878 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil and midazolam (n = 11)
Number of subjects: 35
Study 7777878 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine and midazolam (n = 11)
Number of subjects: 35
Study 2406859 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate (300 mg every 30 minutes, total of 2.4 g in eight doses)
Number of subjects: 31
Study 2406859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 161062 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyphosis gymnastics
Number of subjects: 87
Study 161062 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinebalneotherapy
Number of subjects: 87
Study 161062 — intervention group
Group type: EXPERIMENTAL
Intervention: Differentiated rehabilitation
Number of subjects: 87
Study 31513088 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Tiaogan formula (BSTG) plus traditional Chinese medicine-based psychotherapy (TBP)
Number of subjects: 307
Study 31513088 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus traditional Chinese medicine-based psychotherapy (TBP)
Number of subjects: 307